Skip to main content

Tourmaline Bio, Inc.

TRMLDelisted Oct 28, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001827506

Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.

Q3 2024 vs. Q2 2024

How the institutions holding Tourmaline Bio, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of TRML: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders84192+9
Shares21.2M1.72M21.0M+1.60M (+8.2%)
Value$272.0M$22.2M$540.7M+$290.9M (+116.4%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (22)

Institutions that held Tourmaline Bio, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to TRML in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.1,753,347$45.1M0.00%
Millennium Management LLC509,415$13.1M0.01%
Point72 Asset Management, L.P.338,437$8.70M0.03%
Pictet Asset Management Holding SA247,140$6.35M0.01%
Siren, L.L.C.91,426$2.35M0.12%
StemPoint Capital LP55,523$1.43M0.43%
Brown Advisory Inc39,719$1.02M0.00%
Jane Street Group, LLC21,705$558.0K0.00%
MetLife Investment Management13,886$357.0K0.00%
Mirae Asset Global ETFs Holdings Ltd.12,780$328.6K0.00%
Alliancebernstein L.P.9,270$238.3K0.00%
Manufacturers Life Insurance Company, The8,804$226.4K0.00%
Cresset Asset Management, LLC7,944$204.2K0.00%
Price T Rowe Associates Inc7,753$200.0K0.00%
Catalyst Funds Management Pty Ltd200$5.14K0.00%
GAMMA Investing LLC147$3.78K0.00%
Sterling Capital Management LLC85$2.19K0.00%
Nisa Investment Advisors, LLC67$1.72K0.00%
Lindbrook Capital, LLC56$1.44K0.00%
Signaturefd, LLC54$1.39K0.00%
Russell Investments Group, Ltd.33$8480.00%
US Bancorp20$5140.00%

Sold out (13)

Institutions that held Tourmaline Bio, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of TRML in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Suvretta Capital Management, LLC125,000$1.61M
Renaissance Technologies LLC100,076$1.29M
Artal Group S.A.91,426$1.18M
HighVista Strategies LLC83,397$1.07M
Walleye Capital LLC78,907$1.01M
Cubist Systematic Strategies, LLC37,861$486.9K
UBS Asset Management Americas Inc31,388$403.6K
Jump Financial, LLC27,782$357.3K
Swiss National Bank25,200$324.1K
Alpine Global Management, LLC22,648$291.3K
State of Wisconsin Investment Board11,686$150.3K
Janus Henderson Group PLC11,500$147.7K
Simplex Trading, LLC104$1.00K

Not filed for Q3 2024 yet (1)

Institutions that held Tourmaline Bio, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TRML in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.1,724,216$22.2M